Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APC 366

Drug Profile

APC 366

Alternative Names: APC 366-A; APC 366-C; APC 366-R

Latest Information Update: 15 Oct 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group
  • Class Antiasthmatics; Antithrombotics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Mast cell tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 15 Oct 1998 Discontinued-II for Asthma in United Kingdom (Inhalation)
  • 15 Oct 1998 Discontinued-II for Asthma in USA (Inhalation)
  • 17 Sep 1998 Axys Pharmaceuticals has filed an IND for a dry powder inhaler formulation of APC 366
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top